Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors Life Science Investing
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy Life Science Investing
Seer Urges Stockholders to Vote "FOR" Seer's Highly Qualified Director Nominees on the BLUE Proxy Card TODAY Life Science Investing
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans Life Science Investing
Special Committee of Seer's Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D. Life Science Investing
Lexston Mining Corporation Provides Update on Additional Services from Hillside Consulting and Media Inc. Life Science Investing
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers Life Science Investing
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 Life Science Investing
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
